

F. No. M- 11016/7/2024-NHM-II (8269486)
Ministry of Health and Family Welfare
Government of India
(National Health Mission)

Nirman Bhawan, New Delhi
Dated 2nd July, 2024

To,

Sh. Abhinav Trikha, IAS
Mission Director (NHM),
DoHFW, Government of Punjab,
5th Floor, Prayaas Building,
Sector-38B, Chandigarh


Subject: Administrative approval of supplementary of Hemophilia Pended proposals for FY 2024-26 of State of Punjab- reg.

Sir,

This is in reference to the Administrative approval of Hemophilia pended proposals mentioned in the main RoP 2024-26 issued on dated 16th March 2024 of the State of Punjab.

2. After the examination of the proposal, the Supplementary approval of Rs. 26.99 Cr for FY 2024-25 & Rs. 31.92 Cr 2025-26 is approved for the State of Punjab.
3. After Supplementary approvals, the total approvals for the State of Punjab will now be Rs. 1935.97 Crore (including IM, Immunization Kind Grants & committed liabilities) for FY 24-25 and Rs. 1852.39 Crore (including IM, Immunization Kind Grants) for FY 25-26 respectively.
4. All the conditionalities outlined under the Main RoP/Administrative approval for the FY 2024-26 are applicable to these approvals for FY 2024-26, unless stated otherwise.
5. This issues with the approval of competent authority

Yours sincerely,



Dr Neha Garg
Director (NHM-II)

Annexure-I
(Rs. In Lakhs)

FMR Code	Programme/Theme	S. No.	Scheme/Activity	Amount Proposed (In lakhs)		Amount Recommended (In lakhs)		GoI Remarks
				FY 2024-25	FY 2025-26	FY 2024-25	FY 2025-26	
HSS. 2	Blood Services & Disorders	156	Blood Bank/BCSU/BSU/Thalassemia Day Care Centre	3642.00	4731.00	2699.42	3192.28	<p>FY 24-25</p> <p>1.b. Recommended budget Rs. 2699.42 lakhs the procurement of Anti-hemophilia drugs for - Rs 910 Lakhs Factor VIII @Rs 7 for 500 patients with 20,000IU per patient ie. 7 x 500 x 20,000 IU with 30% buffer - Rs 416 Lakhs for Factor IX @Rs 16 for 100 patients with 20,000 IU per patient i.e. 16 x 100 x 20,000 IU with 30% buffer - Rs 639.60 Lakhs for Factor VII @Rs 41000 for 20 patients 5 mg per episode for 12 episodes per year per patient and 30% buffer - Rs 733.82 Lakhs for APCC @Rs 56 for 500 IU for 12 doses for 20 patients with</p>

FMR Code	Programme/ Theme	S. No	Scheme/ Activity	Amount Proposed (In lakhs)		Amount Recommended (In lakhs)		GoI Remarks
				FY 2024-25	FY 2025-26	FY 2024-25	FY 2025-26	
								<p>8.4 dose range and 30% buffer</p> <p>- Emicizumab not recommended as its not part of IPHS</p> <p>FY 2025-26</p> <p>1.b. Recommended budget of Rs 3192.28 lakhs for the procurement of Anti - hemophilia drugs for following:</p> <p>- Rs 955.50 Lakhs Factor VIII @Rs 7 for 525 patients with 20,000 IU per patient ie. 7 x 525 x 20,000 IU with 30% buffer</p> <p>- Rs 520 Lakhs for Factor IX @Rs 16 for 125 patients with 20,000 IU per patient i.e. 16 x 125 x 20,000 IU with 30% buffer</p> <p>- Rs 799.50 Lakhs for Factor VII @Rs 41000 for 25 patients 5 mg per episode for 12 episodes per year per patient and 30% buffer</p> <p>- Rs 917.28 Lakhs</p>

FMR Code	Programme/ Theme	S. No	Scheme/ Activity	Amount Proposed (In lakhs)		Amount Recommended (In lakhs)		GoI Remarks
				FY 2024-25	FY 2025-26	FY 2024-25	FY 2025-26	
								for APCC @Rs 56 for 500 IU for 12 doses for 25 patients with 8.4 dose range and 30% buffer - Emicizumab not recommended as its not part of IPHS.
